• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders

    Teva Enhances Board of Directors as All Proposals Approved at Annual General Meeting of Shareholders

  2. ADRs End Mostly Higher; Teva , Siemens and Vipshop Trade Actively

    ADRs End Mostly Higher; Teva , Siemens and Vipshop Trade Actively

  3. Global Castration Resistant Prostate Cancer Treatment Market 2017-2021 with Astellas Pharma, Johnson & Johnson, Sanofi & Valeant Dominating - Research and Markets

    Global Castration Resistant Prostate Cancer Treatment Market 2017-2021 with Astellas Pharma, Johnson & Johnson, Sanofi & Valeant Dominating - Research and Markets

  4. Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab)

    Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab)

  5. Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

    Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint

12345

©2017 Morningstar Advisor. All right reserved.